The first-line efficacy rates of anti-LGI1 encephalitis and anti-CASPR2 encephalitis were 92.3% and 83.3%, respectively, which is consistent with the findings of Teng et al. The gene discussed is CNTNAP2; the disease is viral encephalitis.